Combination Chemotherapy in Patients With Newly Diagnosed BPDCN

Exclusion Criteria

• •Cardiac contra-indication to anthracyclines: cardiac dysfunction events (NYHA grade 3 or 4 and/or LVEF\<50%)
• •Hepatocellular abnormalities except if considered related to the BPDCN:
• •1. ASAT (SGOT) and/or ALAT (SGPT) \> 5 x ULN
• •2. Total bilirubin ≥ 2.5 x ULN
• •Creatinine level \>1.5x ULN or creatinine clearance (MDRD)\<50 mL/mn
• •Prior thrombotic event
• •Active hepatitis B or C virus infection
• •HIV positive
• •Serious medical or psychiatric illness that could interfere with the completion of treatment
• •Known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent.
• •Pregnant and lactating female patients
• •Patients diagnosed with or treated for another malignancy within 2 years before study enrollment or with residual disease (basal cell carcinoma or cervical carcinoma in situ patients may be enrolled if they have undergone complete resection)